AcelRx is currently seeking commercial and development partners for ARX-04 (known as DSUVIA™ in the US) and for Zalviso® in select geographies. Our ideal partners have both broad geographic coverage and a demonstrated track record of success in our target markets.
We welcome the opportunity to talk with potential commercialization partners worldwide about licensing relationships, development collaborations, and strategic alliances that complement and extend our own development and commercial capabilities.
To discuss potential partnering opportunities, please contact:
Meera Desai, Ph.D.
Director, Alliance Management and Corporate Development
ARX-04 (known as DSUVIA™ in the US)is an investigational sublingual sufentanil tablet (30 mcg) delivered via a disposable, pre-filled, single-dose applicator. The product-candidate is designed to be administered by a healthcare provider for the management of moderate-to-severe acute pain in a variety of medically supervised settings, including emergency medicine; outpatient, short-stay or ambulatory surgery; and non-surgical patients experiencing moderate-to-severe acute pain in the hospital. In February 2017, AcelRx announced that the FDA accepted the NDA for DSUVIA. AcelRx submitted the Marketing Authorisation Application (MAA) for ARX-04 to the European Medicines Agency (EMA) and review is underway.
Zalviso is currently approved by the European Commission (EC) for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting. It is marketed by Grünenthal Group, AcelRx's licensee in Europe and Australia.